Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers
Circulating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis...
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
Nature Research
2024
|
| _version_ | 1826313638432997376 |
|---|---|
| author | Smith-Byrne, K Hedman, Å Dimitriou, M Desai, T Sokolov, AV Schioth, HB Koprulu, M Pietzner, M Langenberg, C Atkins, J Penha, RC McKay, J Brennan, P Zhou, S Richards, BJ Yarmolinsky, J Martin, RM Borlido, J Mu, XJ Butterworth, A Shen, X Wilson, J Assimes, TL Hung, RJ Travis, RC |
| author_facet | Smith-Byrne, K Hedman, Å Dimitriou, M Desai, T Sokolov, AV Schioth, HB Koprulu, M Pietzner, M Langenberg, C Atkins, J Penha, RC McKay, J Brennan, P Zhou, S Richards, BJ Yarmolinsky, J Martin, RM Borlido, J Mu, XJ Butterworth, A Shen, X Wilson, J Assimes, TL Hung, RJ Travis, RC |
| author_sort | Smith-Byrne, K |
| collection | OXFORD |
| description | Circulating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets. Here we find 40 proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment: 2.27, 1.88-2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [0.79, 0.73-0.85]. We also identify potential adverse effects of protein-altering interventions to reduce cancer risk, such as hypertension. Additionally, we report 18 proteins associated with cancer risk that map to existing drugs and 15 that are not currently under clinical investigation. In sum, we identify protein-cancer links that improve our understanding of cancer aetiology. We also demonstrate that the wider consequence of any protein-altering intervention on well-being and morbidity is required to interpret any utility of proteins as potential future targets for therapeutic prevention. |
| first_indexed | 2024-09-25T04:18:07Z |
| format | Journal article |
| id | oxford-uuid:f100efb4-9804-435e-ac3e-c45cbb9bff1c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:18:07Z |
| publishDate | 2024 |
| publisher | Nature Research |
| record_format | dspace |
| spelling | oxford-uuid:f100efb4-9804-435e-ac3e-c45cbb9bff1c2024-07-20T14:59:00ZIdentifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancersJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f100efb4-9804-435e-ac3e-c45cbb9bff1cEnglishJisc Publications RouterNature Research2024Smith-Byrne, KHedman, ÅDimitriou, MDesai, TSokolov, AVSchioth, HBKoprulu, MPietzner, MLangenberg, CAtkins, JPenha, RCMcKay, JBrennan, PZhou, SRichards, BJYarmolinsky, JMartin, RMBorlido, JMu, XJButterworth, AShen, XWilson, JAssimes, TLHung, RJTravis, RCCirculating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets. Here we find 40 proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment: 2.27, 1.88-2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [0.79, 0.73-0.85]. We also identify potential adverse effects of protein-altering interventions to reduce cancer risk, such as hypertension. Additionally, we report 18 proteins associated with cancer risk that map to existing drugs and 15 that are not currently under clinical investigation. In sum, we identify protein-cancer links that improve our understanding of cancer aetiology. We also demonstrate that the wider consequence of any protein-altering intervention on well-being and morbidity is required to interpret any utility of proteins as potential future targets for therapeutic prevention. |
| spellingShingle | Smith-Byrne, K Hedman, Å Dimitriou, M Desai, T Sokolov, AV Schioth, HB Koprulu, M Pietzner, M Langenberg, C Atkins, J Penha, RC McKay, J Brennan, P Zhou, S Richards, BJ Yarmolinsky, J Martin, RM Borlido, J Mu, XJ Butterworth, A Shen, X Wilson, J Assimes, TL Hung, RJ Travis, RC Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title | Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title_full | Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title_fullStr | Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title_full_unstemmed | Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title_short | Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| title_sort | identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
| work_keys_str_mv | AT smithbyrnek identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT hedmana identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT dimitrioum identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT desait identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT sokolovav identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT schiothhb identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT koprulum identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT pietznerm identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT langenbergc identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT atkinsj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT penharc identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT mckayj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT brennanp identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT zhous identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT richardsbj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT yarmolinskyj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT martinrm identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT borlidoj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT muxj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT butterwortha identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT shenx identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT wilsonj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT assimestl identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT hungrj identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers AT travisrc identifyingtherapeutictargetsforcanceramong2074circulatingproteinsandriskofninecancers |